A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN Smallpox Vaccine in Healthy, Vaccinia-naive Subjects
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 18 Jan 2019 According to a Bavarian Nordic media release, in 2017, the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised an option of USD 37 million to cover development costs associated with this phase III trial required for the eventual approval of the freeze-dried MVA-BN smallpox vaccine.This trial will be initiated in the first half of 2019.
- 05 Oct 2018 Status changed from planning to not yet recruiting.
- 24 May 2018 According to a Bavarian Nordic media release, this study is planned to start in 2019.